Compositions and methods using anti-cs1 antibodies to treat multiple myeloma

Abstract

Compositions and methods for treating MM are provided herein.

1 . A pharmaceutical composition suitable for treating multiple myeloma in a subject, comprising a therapeutically effective amount of HuLuc63 in combination with one or more therapeutic agents, wherein said composition is capable of being administered in a single or multiple dose regimen. 
     
     
         2 . A pharmaceutical composition suitable for treating multiple myeloma in a subject, comprising a therapeutically effective amount of HuLuc63 in combination with a one or more targeted agents, conventional chemotherapeutic agents, hormonal therapy agents, or supportive care agents, and/or combinations thereof, wherein said composition is capable of being administered in a single or multiple dose regimen. 
     
     
         3 . The pharmaceutical composition according to  claim 2 , in which one or more conventional therapeutic agents are selected from the group consisting of thalidomide, vincristine, carmustine, melphalan, cyclophosphamide, doxorubicin, doxorubicin HCl liposome injection, cisplatin, etoposide, ara-C, and one or more hormonal therapy agents selected from the group consisting of dexamethasone and prednisone. 
     
     
         4 . The pharmaceutical composition according to  claim 2 , in which one or more one or more targeted agents are selected from the group consisting of anti-angiogenic agents, inhibitors of growth factor signaling, immunomodulators, inhibitors of protein synthesis, folding and/or degradation, inhibitors of gene expression, pro-apoptotic agents, agents that inhibit signal transduction, other agents, and combinations thereof, 
     
     
         5 . The pharmaceutical composition according to  claim 3 , comprising dexamethasone. 
     
     
         6 . The pharmaceutical composition according to  claim 3 , comprising dexamethasone and thalidomide. 
     
     
         7 . The pharmaceutical composition according to  claim 3 , comprising vincristine, doxorubicin and dexamethasone. 
     
     
         8 . The pharmaceutical composition according to  claim 3 , comprising doxorubicin HCl liposome injection, vincristine and dexamethasone. 
     
     
         9 . The pharmaceutical composition according to  claim 3 , comprising cyclophosphamide. 
     
     
         10 . The pharmaceutical composition according to  claim 3 , comprising dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide and etoposide. 
     
     
         11 . The pharmaceutical composition according to  claim 3 , comprising vincristine, doxorubicin, dexamethasone, and cyclophosphamide. 
     
     
         12 . The pharmaceutical composition according to  claim 3 , comprising doxorubicin HCl liposome injection, vincristine, dexamethasone, and thalidomide. 
     
     
         13 . The pharmaceutical composition according to  claim 1  or  2 , in which HuLuc63 is in an injectable form. 
     
     
         14 . The pharmaceutical composition according to  claim 12 , containing from about 0.5 mg/kg to about 20 mg/kg of HuLuc63. 
     
     
         15 . The pharmaceutical composition according to  claim 1  or  2 , in which administration of said pharmaceutical composition elicits a complete response. 
     
     
         16 . The pharmaceutical composition according to  claim 1  or  2 , in which administration of said pharmaceutical composition elicits a very good partial response. 
     
     
         17 . The pharmaceutical composition according to  claim 1  or  2 , in which administration of said pharmaceutical composition elicits a partial response. 
     
     
         18 . The pharmaceutical composition according to  claim 1  or  2 , in which administration of said pharmaceutical composition elicits a minimal response. 
     
     
         19 . A method for increasing sensitivity of a multiple myeloma cell to a therapeutic agent, comprising contacting the cell with a therapeutically effective amount of HuLuc63. 
     
     
         20 . The method according to  claim 19 , further comprising contacting the cell with a therapeutically effective amount of one or more conventional therapeutic agents selected from the group consisting of thalidomide, vincristine, carmustine, melphalan, cyclophosphamide, doxorubicin, doxorubicin HCl liposome injection, cisplatin, etoposide, ara-C, and one or more hormonal therapy agents selected from the group consisting of dexamethasone and prednisone. 
     
     
         21 . The method according to  claim 19 , wherein the multiple myeloma cell is resistant to the therapeutic agent. 
     
     
         22 . The method according to  claim 21 , further comprising contacting said resistant cell with a therapeutic agent that the cell is sensitive to, said agent selected from the group consisting of one or more conventional therapeutic agents selected from the group consisting of thalidomide, vincristine, carmustine, melphalan, cyclophosphamide, doxorubicin, doxorubicin HCl liposome injection, cisplatin, etoposide, ara-C, and one or more hormonal therapy agents selected from the group consisting of dexamethasone and prednisone. 
     
     
         23 . A method of treating multiple myeloma in a subject, the method comprising administering a first pharmaceutical composition comprising HuLuc63 and a second pharmaceutical composition comprising one or more targeted agents, conventional chemotherapeutic agents, hormonal therapy agents, or supportive care agents, or combinations thereof, wherein said compositions are capable of being administered in single or multiple dose regimens. 
     
     
         24 . A method of treating multiple myeloma in a subject, the method comprising administering a therapeutically effective amount of HuLuc63 in combination with one or more targeted agents selected from the group consisting of anti-angiogenic agents, inhibitors of growth factor signaling, immunomodulators, inhibitors of protein synthesis, folding and/or degradation, inhibitors of gene expression, pro-apoptotic agents, agents that inhibit signal transduction, other agents, or combinations thereof, wherein said compositions are capable of being administered in single or multiple dose regimens. 
     
     
         25 . The method according to  claim 24 , further comprising one or more conventional chemotherapeutic agents and one or more hormonal agents. 
     
     
         26 . The method according to  claim 25 , in which one or more conventional therapeutic agents are selected from the group consisting of thalidomide, vincristine, carmustine, melphalan, cyclophosphamide, doxorubicin, doxorubicin HCl liposome injection, cisplatin, etoposide, ara-C, and one or more hormonal therapy agents selected from the group consisting of dexamethasone and prednisone. 
     
     
         27 . The method according to  claim 23 , in which HuLuc63 is administered intravenously at a dosage from approximately 0.5 mg/kg to approximately 20 mg/kg. 
     
     
         28 . The method according to  claim 23 , in which HuLuc63 is administered concurrently with the pharmaceutical composition comprising one or more of said targeted agents, conventional chemotherapeutic agents, hormonal therapy agents, supportive care agents, or combinations thereof. 
     
     
         29 . The method according to  claim 28 , in which said administration elicits a complete response. 
     
     
         30 . The method according to  claim 28 , in which said administration elicits a very good partial response. 
     
     
         31 . The method according to  claim 28 , in which said administration elicits a partial response. 
     
     
         32 . The method according to  claim 28 , in which said administration elicits a minimal response. 
     
     
         33 . A method of treating multiple myeloma in a subject, comprising administering a therapeutically effective amount of HuLuc63, a therapeutically effective amount of one or more targeted agents, conventional chemotherapeutic agents, hormonal therapy agents, supportive care agents, or combinations thereof, and a pharmaceutically acceptable carrier, wherein said composition is capable of being administered in a single or multiple dose regimen.